Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories.

The 2024 annual reports of major Chinese IVD companies released.

The Trump administration's fiscal-year 2026 budget proposal calls for a roughly 40 percent cut in funding for the National Institutes of Health.

Diasorin (FTSE MIB: DIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second1 of its 3 multiplex molecular panels for blood culture pathogen identification on the LIAISON PLEX® system.

BioMérieux's year-over-year sales grew approximately 14 percent for the first quarter, the firm reported on Thursday, prompting it to confirm its previous full-year revenue guidance.

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada).

Chinese President Xi Jinping said here Thursday that building a China-Cambodia community with a shared future is a choice of history and the people.

China and Malaysia have agreed to build a high-level strategic China-Malaysia community with a shared future to accelerate their modernization efforts and jointly promote regional and global prosperity and stability.

GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that Health Canada has approved SPINEstat™, a first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), as a Class II medical device. By detecting auto-antibodies to the 14-3-3eta protein, SPINEstat™ provides an important new clinically validated and objective biomarker to aid in the early and accurate diagnosis of axSpA.